Madeira News
5.07.10: Pediatric Labelling: A Different Point of View
Currently, more than two-thirds of medicine prescribed to children has not been studied and adequately labeled due to a complex and expensive development process. Pete Joiner, President and CEO of Madeira Therapeutics, discusses the challenges of pediatric drug labelling along with several procedures that should be explored in order to improve the process. Joiner expresses his aspirations of “a future in which children are safer and manufacturers have the tools to make pediatric drug research more effective and efficient.”
May 2010 – International Clinical Trials
Click here to view PDF of the article
Samedan Ltd. Pharmaceutical Publishers
4.27.10: Madeira Therapeutics to Present at the 2010 BIO International Convention
Pete Joiner, President and CEO of Madeira Therapeutics, will present at the BIO International Convention on May 4, 2010 in Chicago, Illinois. Joiner will address transitioning between small and large pharma during the Career Management Program alongside five additional company representatives. Visit Madeira Therapeutics at the Kansas pavilion, booth 4506.
4.23.10: Health Care Reform May Assist Biotech Companies
A section of the Health Care Reform Bill has formed a $1 billion Qualifying Therapeutic Discovery Project Credit program, which will increase funding for on-the-rise biotech companies, such as Madeira Therapeutics. Pete Joiner, President and CEO of Madeira Therapeutics, expresses his enthusiasm and hopes for this program.
2010-04-16 Kansas City Business Journal
Click here to view the original online article
4.12.10: Madeira Therapeutics to Present at Silicom Ventures Meeting
Pete Joiner, President and CEO of Madeira Therapeutics, will present at Silicom Ventures’ monthly meeting on April 13, 2010, in Mountain View, California. One of seven company representatives to speak and participate in the poster session, Joiner will communicate Madeira Therapeutics’ mission to develop safe and efficacious pediatric medicines in pursuit of gaining potential investor support.
3.11.10: Madeira Therapeutics Looks to Work with Children’s Mercy’s Center for Personalized Medicine and Therapeutic Innovation
Madeira Therapeutics looks to partner with Children’s Mercy and its Center for Personalized Medicine and Therapeutic Innovation in identifying specific populations in need of medications, primarily pediatrics. President and CEO of Madeira Therapeutics, Pete Joiner, gives his outlook on the potential of this cooperation.
2010-03-05 Kansas City Business Journal
Click here to view the original online article
3.11.10: Madeira Therapeutics Selected to Present at the 2010 World’s Best Technologies Showcase
(LEAWOOD, KS; March 10, 2010) – Madeira Therapeutics, a Kansas-based company specializing in pediatric pharmaceuticals, is one of over 100 companies and technology innovators from across the nation and around the world that will compete for top honors at the 2010 World’s Best Technologies (WBT) Showcase, March 16-17, in Arlington, Texas. view more
3.5.10: Madeira Therapeutics Looking to Secure Investors for the Development of a Liquid Statin For Children
Pete Joiner, President of Madeira Therapeutics discusses securing funds for the development of pediatric medicines and partnerships being formed internationally.
2010-01-26 Pharmawire
Click here to view the original online article
2.9.10: MADEIRA THERAPEUTICS SPEAKS AT THE INVESTOR ARENA MEETING, MILAN, ITALY
The below translation is from an interview with Pete Joiner, President and CEO of Madeira Therapeutics, who spoke at the recent Investor Arena Meeting of Intesa Sanpaolo.
“Ours is a humanitarian mission,” stated Pete Joiner, CEO of Madeira Therapeutics, a business started in Kansas three years ago focusing only on pharmaceuticals for children. 70% of the prescriptions for children, in fact, are not approved by the authorities. “The goal is to create formulations adapted to those under 18 years old and approved by the FDA and EMEA, especially those that are difficult to swallow. All while keeping an eye on generics.” From the US to Europe, the distance is short: “We are just concluding negotiations for a development program in Spain.”
Click here for original article
1.26.10: LIVE FROM THE ANNUAL DRUG DELIVERY PARTNERSHIPS MEETING
Listen to Peter Joiner, Chief Executive Officer of Madeira Therapeutics speak on pediatric drug development. Click here
1.20.10: MADEIRA THERAPEUTICS TO SPEAK AT THE ANNUAL DRUG DELIVERY PARTNERSHIPS MEETING
(LEAWOOD, KS; January 20, 2010) - Madeira Therapeutics, a Kansas-based company specializing in pediatric pharmaceuticals, announced today that Peter Joiner, Madeira president and chief executive officer, will address the pediatric segment of the “Drug Delivery and Development for Specialized Populations: Pediatric and Geriatric Products” workshop at the 14th Annual Drug Delivery Partnerships Meeting held January 25-27, 2010, in Orlando, FL. view more
11.13.09: Studies suggest overweight kids are coronary time bombs
CNN recently reported that, with childhood obesity on a disturbing rise, children are becoming coronary time bombs. The evidence is mounting that children are trading playing outside for television and video games. At Madeira Therapeutics, we understand that there is a combination of circumstances contributing to the childhood obesity rate, which has tripled since 1970. We have found heterozygous familial hypercholesterolemia (HeFH) preconditions some children to develop cardiovascular complications, while a less active, more fast food-minded culture has worsened the issue.
While education regarding the urgency of this situation is intensifying, medical professionals are currently burdened with the lack of appropriate treatment options for its complications. Physicians are often compelled to resort to off-label prescriptions of adult formulations, a practice that lacks suitable dose titrations and standardized regulations.
Madeira Therapeutics aims to alleviate some of the pressure by developing a liquid statin to lower cholesterol in children when diet and exercise are not enough. We strongly believe that exercise and education are key components to curbing the obesity epidemic. However, since a recent American Heart Association study likened the arteries of obese children to those of 45 year-olds, it is clear that efficacious treatment options need to be available for this trend to turn around.
Pete Joiner
President & CEO Madeira Therapeutics
View article - CNN Health
10-27-09: The Need for Pediatric Liquid Formulations
When liquid Tamiflu for children ran short recently, the FDA authorized pharmacists to mix their own liquid version of the drug using expired Tamiflu capsules and a commercial cherry syrup. The debacle occurring with the country facing its most challenging flu season in years underscores Madeira Therapeutics’ mission: more drugs need to be available in true pediatric formulations to treat children.
With only a quarter of pharmaceuticals labeled for pediatric use, physicians often are forced to write off-label prescriptions. However, using extemporaneous formulations with untested bioavailability and stability in children is clearly a dangerous practice. Doesn’t it make more sense to accelerate programs to bring important medicines to market that are intended and labeled for pediatric use? Using the 505(b)(2) approval pathway, the FDA allows adult drugs to be expediently reformulated for children. Madeira Therapeutics has determined a fast-track development timetable for three liquid formulated pediatric products.
I am hopeful the Tamiflu liquid shortage will open the industry’s and consumers’ eyes to the urgent need for specialized pediatric drugs. Madeira Therapeutics is one of the few drug development companies with a dedicated focus on this niche market − pediatric formulations that are sized to fit.
— Peter R. Joiner, CEO Madeira Therapeutics
View article - Expired Tamiflu OK'd for Liquid Use
10-26-09: Madeira Therapeutics to Present at Second Annual Boston Biotech R&D Conference
(BOSTON, MA; October 26, 2009) – Madeira Therapeutics announced today that Peter Joiner, CEO, will present at the 2009 Boston Biotech R&D Conference at 3:20 PM on October 27, 2009, at Harvard Medical School in Boston, Massachusetts. This conference will bring luminaries from top academic institutions that have been instrumental in establishing the strong Boston biotech community together with executives from several of the area’s most promising emerging biopharmaceutical companies, as well as leaders from the venture capital community and equity markets. view more
10-2-09: Madeira Therapeutics Participates as a Keynote Speaker at the 7th Annual BioNetwork Conference in California
(LEAWOOD, KS; October 2, 2009)– Peter Joiner, president and chief executive officer of Madeira Therapeutics, a Kansas-based company specializing in pediatric pharmaceuticals, will serve as a keynote speaker and panelist at the 7th Annual BioNetwork Conference at the Ritz Carlton in Laguna Niguel, California, on October 5-7, 2009. view more
5-2-09: MADEIRA THERAPEUTICS TO PRESENT AT BIO INTERNATIONAL CONVENTION
LEAWOOD, KS; May 6, 2009)- Madeira Therapeutics, a Kansas-based company specializing in pediatric pharmaceuticals, announced today that Peter Joiner, Madeira president and chief executive officer, will present an overview of the company at the annual BIO International Convention on May 20, 2009, from 9:00-9:15 am in room 316 at the World Congress Center in Atlanta, Georgia. view more
3-25-09: MADEIRA THERAPEUTICS TO PRESENT AT THE INVESTMIDWEST CONFERENCE
(March 25, 2009; Leawood, KS)- Madeira Therapeutics, a Kansas-based company specializing in pediatric pharmaceuticals, announced today that Peter Joiner, Madeira president and chief executive officer, will present an overview of the company at the 2009 InvestMidwest Conference on April 1, 2009, at 11:58am at the Westin Crown Center Hotel in Kansas City. view more
1-13-09: DR. GREGORY L. KEARNS, PHARM.D., PH.D., JOINS MADEIRA THERAPEUTICS BOARD OF ADVISOR
(January 13, 2009; Leawood, KS) - Madeira Therapeutics, a company specializing in pediatric pharmaceuticals, is pleased to announce that Dr. Gregory L. Kearns, Pharm.D., Ph.D., Chairman of the Department of Medical Research and Director of the Pediatric Pharmacology Research Unit at Children's Mercy Hospitals and Clinics in Kansas City, Missouri, has elected to serve as a member of the Company's Board of Advisors. view more
1-6-09: MADEIRA THERAPEUTICS TO PRESENT AT THE BIOTECH SHOWCASE 2009 IN SAN FRANCISCO
(January 6, 2009; Leawood KS) - Madeira Therapeutics announced today that Peter Joiner, Madeira president and chief executive officer, will present an overview of the company at the 2009 Biotech Showcase on January 14, 2009. view more
8-26-08: MADEIRA THERAPEUTICS NAMES DAVID TOUSLEY TO BOARD OF ADVISORS
(August 26, 2008; Leawood KS) - Madeira Therapeutics, a new drug development company specializing in pediatric pharmaceuticals, is pleased to announce the addition of David L. Tousley, MBA, CPA, to the Madeira Board of Advisors. view more
7-17-08: MADEIRA THERAPEUTICS DEVELOPING A STATIN, A CHOLESTEROL-LOWERING PRODUCT, FORMULATED SPECIFICALLY FOR CHILDREN
(July 17, 2008; Leawood, KS) - The American Academy of Pediatrics (AAP) released new guidelines on July 7, 2008, recommending that some children as young as 8 years old be given cholesterol-fighting drugs to ward off future heart problems. view more
06-24-08: MADEIRA THERAPEUTICS NAMES J. LYLE BOOTMAN TO BOARD OF Advisors
(June 24, 2008; Leawood, KS) - Madeira Therapeutics, a new drug-development company specializing in pediatric pharmaceuticals, has announced the addition of a notable pharmaceutical industry veteran to its Board of Advisors. view more
04-29-08: Madeira Therapeutics Announces Company Launch and Novel Drug Development Strategy
(April 29, 2008; Leawood, KS) - Peter R. Joiner, CEO, announced today the launch of Madeira Therapeutics, a new drug-development company specializing in pediatric pharmaceuticals. view more
